Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Iovance Biotherapeutics Study Team
CONTACT
Lead
Iovance Biotherapeutics, Inc.
The study will enroll participants with advanced endometrial cancer who previously received treatment with platinum-based chemotherapy and an anti-programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) agent in a recurrent or advanced setting, either sequentially or in combination.
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted